Aigen Investment Management LP lowered its holdings in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 16.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,083 shares of the medical instruments supplier’s stock after selling 419 shares during the period. Aigen Investment Management LP’s holdings in Glaukos were worth $271,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Values First Advisors Inc. bought a new position in Glaukos during the 3rd quarter worth approximately $25,000. GAMMA Investing LLC raised its stake in Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after buying an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in Glaukos in the second quarter valued at $187,000. Brighton Jones LLC bought a new stake in Glaukos during the second quarter valued at $208,000. Finally, Procyon Advisors LLC acquired a new stake in Glaukos during the 3rd quarter worth about $210,000. Institutional investors and hedge funds own 99.04% of the company’s stock.
Glaukos Stock Performance
Shares of Glaukos stock opened at $138.42 on Friday. Glaukos Co. has a 52 week low of $59.22 and a 52 week high of $145.84. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The business has a 50 day moving average price of $130.92 and a 200-day moving average price of $122.22. The company has a market cap of $7.63 billion, a PE ratio of -45.83 and a beta of 1.02.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on GKOS shares. Needham & Company LLC raised their target price on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Truist Financial raised their price target on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Monday, October 14th. BTIG Research upped their price objective on shares of Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Finally, Wells Fargo & Company raised their target price on Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $134.55.
Read Our Latest Report on GKOS
Insider Activity at Glaukos
In other news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 8.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,275 shares of company stock valued at $1,354,967 over the last ninety days. Corporate insiders own 6.40% of the company’s stock.
Glaukos Profile
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Recommended Stories
- Five stocks we like better than Glaukos
- The Risks of Owning Bonds
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- How to Calculate Stock Profit
- Top-Performing Non-Leveraged ETFs This Year
- How to Start Investing in Real Estate
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.